MLYSMineralys Therapeutics, Inc.
What is the market doing?
The market is leaning against it: in a downtrend (−19% vs 200-day) and heavily shorted (+11% of shares).
In a downtrend, below its 50- and 200-day averages. Oversold (RSI 28). Price is −19% vs its 200-day average.
Insiders were net sellers over the 90 days ending Oct 8, 2026; selling is often routine (taxes, diversification).
Heavily shorted, settled Sep 15, 2026, about a week of normal trading to cover. Down 1.6% since the previous count, up from 10.5% of shares outstanding three months ago.
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. Insider selling is often routine (taxes, diversification); only cluster buying is a strong tell.
How MLYS is trading
Mineralys Therapeutics, Inc. is −41% over the past year while the S&P 500 is +18%: 59 points behind the market.
1-year return · S&P 500 +18%
- vs 200-day average
- −19%
vs 200-day average · a clear downtrend
- RSI (14)
- 28
RSI (14) · oversold, sold harder than it has been bought
- Below its 52-week high
- 51%
Below its 52-week high
Details›
- Last close2026-10-09
- $23.36
- 1 monthS&P 500 +2.7%
- −20%
- 1 yearS&P 500 +18%
- −41%
- vs 50-day average$26.51
- −12%
- 52-week high
- $47.33
- 52-week low
- $21.95
- Annualised volatility
- 93%
- Insider buying, net, 6 monthsForms 3/4/5 to 2026-10-08
- −$3.0M
| Year | Return |
|---|---|
| 2026 (year to date) | −36% |
| 2025 | +195% |
| 2024 | +43% |
| Month | Years | Positive | Average |
|---|---|---|---|
| Jan | 3 | 1 of 3 | −1.4% |
| Feb | 3 | 1 of 3 | +8.1% |
| Mar | 4 | 1 of 4 | +9.6% |
| Apr | 4 | 0 of 4 | −7.8% |
| May | 4 | 4 of 4 | +10% |
| Jun | 4 | 1 of 4 | −5.2% |
| Jul | 4 | 3 of 4 | −1.1% |
| Aug | 4 | 2 of 4 | −1.1% |
| Sep | 4 | 1 of 4 | +29% |
| Oct | 4 | 2 of 4 | −1.9% |
| Nov | 3 | 1 of 3 | −4.3% |
| Dec | 3 | 1 of 3 | +3.2% |
End-of-day closes from IEX; the S&P 500 comparison uses SPY over the same window. Prices are a reference point, not a basis for trading decisions.